Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS).

16 de noviembre de 2026 actualizado por: M.D. Anderson Cancer Center

This is a single-center, Phase 1/2 clinical trial evaluating the safety, tolerability, RP2D, and preliminary efficacy of ZEN003694 in combination with RT in patients with metastatic UPS and MFS who have completed first- or second- line doxorubicin-based chemotherapy without disease progression.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

Primary Objective:

To evaluate the objective response rate (ORR) according to RECIST v1.1 at 12 weeks in patients treated with ZEN003694 and RT following first- or second- line doxorubicinbased chemotherapy compared to standard of care approach of surveillance.

Secondary Objectives:

  • To estimate PFS following treatment with ZEN003694 and RT after first- or second- line doxorubicin-based chemotherapy.
  • To estimate the 12-month local control rate and time to local recurrence in primary and metastatic irradiated lesions local control rate.
  • To estimate OS following treatment with ZEN003694 and RT after first- or second- line doxorubicin-based chemotherapy.
  • To characterize the safety profile of ZEN003694 in combination with RT following first- or second- line doxorubicin-based chemotherapy using CTCAE v6.0.
  • Key secondary translational objective: To characterize treatment-induced changes in the tumor microenvironment using paired tumor biopsies obtained at baseline and Week 12/EOT, including changes in DNA damage, immune-cell infiltration, antigen presentation, and PD-L1 expression.

Exploratory Objective:

We will perform exploratory analyses on tumor biopsy and blood samples collected at baseline and post-treatment at the indicated time points to identify potential predictive biomarkers of response. These may include immunohistochemistry (IHC)-based quantification of g-H2AX foci (as surrogate for degree of DNA damage induced by the treatment), tumor-associated antigens and neoantigens, tumor-infiltrating lymphocytes (TILs), tumor PD-L1 expression, and circulating tumor DNA (ctDNA) analysis.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

57

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • UT MD Anderson
        • Contacto:
        • Investigador principal:
          • Michael Nakazawa, MD, PHD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Disease Characteristics

  • Histologically confirmed Stage IV metastatic UPS/MFS. Pathologic terms may include pleomorphic undifferentiated sarcoma, unclassified spindle cell sarcoma, spindle cell sarcoma not otherwise specified, pleomorphic spindle cell sarcoma, or pleomorphic fibroblastic sarcoma.

    • Patients must have completed at least 4 and no more than 6 cycles of doxorubicin-based first or second-line chemotherapy (single agent or in combination) at least 4 weeks out and within 12 weeks prior to enrollment and have not experienced progressive disease documented per RECIST 1.1 since starting doxorubicin for this current episode of sarcoma.

  • Patients must have measurable disease by RECIST 1.1. Previously ablated/ radiated/treated areas can only be counted towards measurable disease if there is unequivocal progression after directed therapy. Patients must have at least one lesion amenable safely to radiotherapy on trial AND at least one other lesion which is measurable per RECIST 1.1.

  • Participant will have tumor lesion(s) or metastases amenable to biopsy, excluding bone metastases, as confirmed by a radiologist, if appropriate, and as deemed safe by the Investigator. If there is only one target lesion per RECIST 1.1 which is accessible to biopsy, this lesion should be at least 2cm. 2) Patients Characteristics

  • Age ≥18 years.

  • ECOG performance status ≤2 (Karnofsky ≥60%,).

  • Life expectancy of >3 months, as determined by the investigator.

  • Ability to swallow and retain oral medication.

  • Ability to understand and the willingness to sign a written informed consent document and comply with study procedures.

    3) Concurrent Cancer Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial 4) Organ and Marrow Function Requirements

Patients will have adequate organ and marrow function as defined below:

Hemoglobin ≥ 8 g/dL. Absolute neutrophil count ≥1,300/mcL Platelets ≥100,000/mcL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert's syndrome, who must have total bilirubin < 2 x institutional ULN ) AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN for age Calculated creatinine clearance ≥ 50 mL/min (via CKD-EPI eGFR) 5) CNS and Cardiac Requirements

  • Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and has been clinically stable for at least 1 month.

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients with such risk should be class 2B or better.

  • Patients should not have a QTcF >450 msec or history of torsades de pointes or history of congenital long QT syndrome. Reproductive/Contraception Requirements The effects of ZEN003694 on the developing human fetus are unknown. For this reason and because agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy UT MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

    • Postmenopausal (no menses in greater than or equal to 12 consecutive months).
    • History of hysterectomy or bilateral salpingo-oophorectomy.
    • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
    • History of bilateral tubal ligation or another surgical sterilization procedure.
  • Men and women treated or enrolled on this protocol must be surgically sterile or if sexually active with a female partner of child-bearing potential, participants must agree to use two methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 4 months after the last dose of ZEN003694.

  • Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Exclusion Criteria:

  1. Concurrent Treatments and Investigational Agents

    • Prior BET-targeted therapy for sarcoma.

    • Patients who are receiving any other investigational agents or have received any other investigational agent within 3 weeks prior to enrollment.

    • Treatment with a bone-targeted radionuclide within 6 weeks of first administration of study drug.

    • Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and initiation of treatment on trial.

    • Participants requiring strong inhibitors or strong inducers of CYP3A4 enzymes, as well as sensitive substrates of CYP3A3, CYP1A2 and CYP2C19 are ineligible. Strong inhibitors of CYP3A4 must be discontinued for at least 7 days and strong CYP3A inducers at least 14 days or 5 half-lives prior to the first dose of ZEN003694 and throughout the study.

    • Acid reducing agents (PPI, H2 blockers and antacids) may alter the pharmacokinetics of ZEN003694 by reducing ZEN003694 exposure. Participants receiving proton pump inhibitors (PPI) are ineligible. Avoid H2 blockers or antacids 10 to 12 hours before and 2 hours after ZEN003694 administration. Stagger the dosing of ZEN003694 and an antacid by at least 2 hours.

      • Received medications known to prolong QTc within 5 half-lives before the first dose of the study treatment. List of medications that prolong QTc can be obtained from micromedex or Lexidrug

    • Administration of a live vaccine within 28 days of starting study treatment and for up to 1 month after the final dose of study treatment or anticipation that such vaccine will be required during the study. Note: mRNA-based vaccines for COVID-19 are allowed as well as inactivated flu vaccines.

    • Has had or is scheduled to have major surgery <28 days prior to the first dose of study treatment.

  2. Other comorbidities affecting participation

    • Evidence of severe or uncontrolled systemic disease or psychiatric illness that, in the investigator's judgment, would limit safety or compliance.
    • Historically positive for human immunodeficiency virus (HIV) (screening test for HIV not required in the USA); or known active hepatitis B defined as positive HBV DNA viral load or as defined by related guidelines (CDC guidelines in the USA); or hepatitis C virus (HCV) unless previously treated and viral load is undetectable. HBV and HCV tests are not required as part of the screening if patient has no history of hepatitis B or C or risk factors of exposure.
    • Participants with bleeding disorder or taking coumadin. Use of direct oral anticoagulants (DOAC) (e.g. apixaban, rivaroxaban) and low molecular weight heparin is allowed.
    • Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, or any other condition that could compromise safety or the patient's participation in the study.
    • Impairment of gastrointestinal function that may significantly alter the absorption of ZEN003694.
    • Any condition which, in the opinion of the investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Phase 1 Dose Escalation: Treatment with ZEN003694 + RT

Given orally once daily

Otros nombres:
  • ZEN-3694

The radiation therapy is to be delivered using a linear accelerator or proton gantry.

Otros nombres:
  • Radioterapia
Experimental: Phase 2 Randomized Expansion Arm A: Treatment with ZEN003694 + RT

Given orally once daily

Otros nombres:
  • ZEN-3694

The radiation therapy is to be delivered using a linear accelerator or proton gantry.

Otros nombres:
  • Radioterapia
Experimental: Phase 2 Randomized Expansion Arm B: Observation

Given orally once daily

Otros nombres:
  • ZEN-3694
Experimental: Phase 2 Randomized Expansion Arm C: Treatment with ZEN003694 Alone

Given orally once daily

Otros nombres:
  • ZEN-3694

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and Adverse Events (AEs)
Periodo de tiempo: Through study completion; an average of 1 year

ncidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

Through study completion; an average of 1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Michael Nakazawa, MD, PHD, UT MD Anderson

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

31 de mayo de 2027

Finalización primaria (Estimado)

31 de diciembre de 2030

Finalización del estudio (Estimado)

31 de diciembre de 2032

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2026-1208
  • NCI-2026-08622 (Otro identificador: NCI-CTRP Clinical Trials Registry)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir